← Eichor
Condition: Platelet Transfusion Refractoriness Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Platelet Transfusion Refractoriness

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Phase 1/Phase 2 · 1 location(s) · Keymed Biosciences Co.Ltd · NCT06792019RN1201 Injection in the Treatment of Antibody-Mediated Diseases
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07072247Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06254560
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.